Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03 2023 - 4:01PM
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that
it will present at the 41st Annual J.P. Morgan Healthcare
Conference on Monday, January 9, 2023 at 1:30 p.m. Pacific
Time (4:30 p.m. Eastern Time).
A live webcast of Kiniksa’s presentation will be accessible
through the Investors & Media section of the company’s website
at www.kiniksa.com. A replay of the webcast will also be available
on Kiniksa’s website within approximately 48 hours after the
event.
About KiniksaKiniksa is a biopharmaceutical
company focused on discovering, acquiring, developing, and
commercializing therapeutic medicines for patients suffering from
debilitating diseases with significant unmet medical need.
Kiniksa’s portfolio assets, ARCALYST®, KPL-404, and mavrilimumab,
are based on strong biologic rationale or validated mechanisms,
target underserved conditions, and offer the potential for
differentiation. These assets are designed to modulate
immunological pathways across a spectrum of diseases. For more
information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor and Media ContactRachel
Frank(339) 970-9437rfrank@kiniksa.com
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Apr 2023 to Apr 2024